NKTX

Business Context and Reporting Period

Nkarta, Inc. (NKTX) is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. The company's lead product candidate is NKX019, a CAR NK-cell therapy targeting the CD19 antigen. This report covers the quarterly period ended June 30, 2025.

In March 2025, the company executed a reduction in force (RIF) affecting approximately 34% of its workforce to streamline operations and focus resources on clinical data updates for NKX019. The company has no approved products and has not generated any revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $3.5 million for the three months ended June 30, 2025, compared to the same period in 2024. This reduction was primarily driven by lower personnel costs due to the March 2025 reduction in force.
• R&D Expenses: R&D expenses decreased by $2.4 million (QoQ) and $3.4 million (YoY six-month) due to lower headcount and the deprioritization of the NKX101 program. These savings were partially offset by increased clinical spending for the NKX019 autoimmune trials.
• G&A Expenses: G&A expenses decreased by $1.2 million for the quarter but increased by $3.7 million for the six-month period compared to 2024. The six-month increase was primarily due to $5.1 million in severance costs associated with the reduction in force.
• Interest Income: Interest income decreased by $1.8 million for the quarter and $0.6 million for the six-month period, attributed to lower average investment balances and interest rates.
• Liquidity: Cash and investments increased from $27.9 million (cash only) at year-end 2024 to $334.0 million (including investments) as of June 30, 2025, supported by a net increase in cash of $25.5 million during the first half of 2025.

Guidance, Outlook, and Risks

Outlook and Capital Needs: Management believes current cash, cash equivalents, and investments of $334.0 million are sufficient to fund operations for at least 12 months from the filing date. The company expects to continue incurring significant losses as it advances clinical trials for NKX019. Future funding will likely be required through equity or debt financings, which may cause dilution.

Clinical Updates:

• Ntrust-1: A Phase 1 trial for NKX019 in lupus nephritis (LN) and primary membranous nephropathy (pMN). The company modified the lymphodepleting conditioning regimen to a combination of fludarabine and cyclophosphamide.
• Ntrust-2: A Phase 1 trial for NKX019 in systemic sclerosis, myositis, and ANCA-associated vasculitis.
• Deprioritization: The company has deprioritized the development of NKX019 for B-cell malignancies and the NKX101 program for hematologic malignancies to focus on autoimmune indications.

Key Risks:

• Financial: History of significant losses and no revenue; reliance on future capital raises.
• Development: Clinical trials are lengthy and uncertain; enrollment challenges in autoimmune trials; potential for adverse events.
• Manufacturing: Reliance on a sole supplier (Miltenyi) for critical manufacturing steps; complexity of scaling cell therapy production.
• Intellectual Property: Dependence on licensed technology from National University of Singapore and St. Jude; potential patent challenges.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $334.0 million cash position against the projected burn rate, considering the recent cost-cutting measures.
• Severance Liability: Confirm the remaining accrued liability for the March 2025 reduction in force ($1.37 million as of June 30, 2025) and its impact on future quarters.
• Clinical Enrollment: Monitor patient enrollment rates in the Ntrust-1 and Ntrust-2 trials, as delays are a significant risk factor cited by management.
• Manufacturing Supply Chain: Assess the risk associated with the sole supplier for the CliniMACS Plus system and potential tariff impacts on reagent costs.
• Deprioritized Programs: Review the strategic rationale and financial impact of halting development for NKX019 in malignancies and the NKX101 program.